Ignite Creation Date:
2025-12-24 @ 1:57 PM
Ignite Modification Date:
2026-01-04 @ 5:41 PM
Study NCT ID:
NCT02438995
Status:
TERMINATED
Last Update Posted:
2021-11-03
First Post:
2015-05-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Sponsor:
Northwell Health
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-05
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-06
First Submit QC Date:
None
Study First Post Date:
2015-05-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-27
Last Update Post Date:
2021-11-03
Last Update Post Date Type:
ACTUAL